MOVIPREP
LOE Approachingpolyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate
NDAORALFOR SOLUTION
Approved
Aug 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
10
Data completeness
4/8 — Partial
MOVIPREP (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, ascorbic acid, sodium ascorbate) by Bausch Health is 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, which induce a laxative effect. First approved in 2006.
Drug data last refreshed 13h ago · AI intelligence enriched 15h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MOVIPREP is an oral solution containing polyethylene glycol 3350 and electrolytes (sodium sulfate, sodium chloride, potassium chloride) plus ascorbic acid and sodium ascorbate for bowel preparation. It induces a osmotic laxative effect by increasing water retention in the colon, producing loose stools to cleanse the bowel prior to colonoscopy or other diagnostic procedures. Patients typically use this product the day before a gastrointestinal procedure.
$0.073BPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Medicare spending, indicating a mature market with declining team investment and shift toward generic/OTC competition.
Mechanism of Action
3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid, which induce a laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.
Started Oct 2014
849 enrolled
Colorectal CancerColorectal CarcinomaColon Cleansing
Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation
Started Nov 2012
140 enrolled
Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.
A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)
Started Nov 2011
398 enrolled
Colorectal Cancer
Mode of Action of Moviprep
Started Sep 2011
72 enrolled
Functional ConstipationIrritable Bowel Syndrome Characterized by Constipation
Comparing Two Different Ways to Take MoviPrep® Before Colonoscopy
Started Dec 2008
125 enrolled
Colonoscopy
Worked on MOVIPREP at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.